A Denial Is Not the Final Answer

If your insurance has denied coverage for a GLP-1 medication, you're in large company — and you have options. Well-documented insurance appeals succeed roughly 30 to 50 percent of the time, and many initial denials are automated decisions triggered by incomplete documentation rather than genuine ineligibility. The appeal process exists specifically because insurers recognize that first-pass denials don't always get it right.

Step 1: Understand Why You Were Denied

Before you can fight a denial, you need to know the specific reason behind it. Request the denial in writing — your insurer is legally required to provide this. The denial letter should include the specific clinical criteria you didn't meet, the policy provisions the insurer relied on, information about your appeal rights and deadlines, and contact information for the appeals department.

Common denial reasons fall into several categories: you don't meet the plan's BMI or comorbidity thresholds, you haven't completed required step therapy (trying other treatments first), the medication is on a non-preferred tier or not on the formulary at all, the prior authorization documentation was incomplete, or the plan categorically excludes weight-loss medications.

Critical distinction: If your plan categorically excludes weight-loss medications (the drug category itself is not covered), a standard appeal is unlikely to succeed. In this case, you may need to request a formulary exception or explore alternative access pathways such as manufacturer programs, telehealth platforms, or the diabetes indication if clinically appropriate.

Step 2: Gather Stronger Documentation

The most effective appeals are specific, criteria-based, and written for an insurance reviewer. Work with your healthcare provider to assemble a letter of medical necessity that includes your exact diagnosis and the indication being treated (type 2 diabetes vs. obesity vs. cardiovascular risk reduction), objective clinical data including BMI, weight trajectory over time, A1C and relevant lab results, a list of all qualifying comorbidities with supporting documentation, every treatment you've previously attempted and the outcome of each (ineffective, not tolerated, contraindicated), a clear explanation of why the requested GLP-1 is appropriate versus alternatives, and specific references to published clinical guidelines supporting the request.

The appeal works best when it mirrors the insurer's own criteria. If the plan requires a BMI threshold plus a comorbidity, your appeal should put those exact numbers and diagnoses front and center.

Step 3: File the Internal Appeal

Most plans offer two levels of internal appeal. The first-level appeal is reviewed by a different reviewer than the one who made the original denial decision. Submit your appeal within the deadline stated in the denial letter — this is typically 30 to 180 days depending on your plan, but timelines vary. Include your completed appeal form (available from the insurer), the letter of medical necessity from your physician, all supporting clinical documentation, and a copy of the original denial letter.

For the strongest possible appeal, have your provider reference the specific policy language from the denial and address each criterion point by point.

Step 4: Second-Level Appeal

If the first appeal fails, most plans allow a second-level internal appeal. This is typically reviewed by a medical director or peer physician reviewer. At this stage, consider including additional supporting evidence such as peer-reviewed clinical studies relevant to your case, letters from specialists (endocrinologists, cardiologists) supporting medical necessity, or documentation of health deterioration or risk progression that strengthens the urgency of treatment.

Step 5: External Review

If both internal appeals are denied, you have the right to request an external review. This is conducted by an independent third-party organization not affiliated with your insurance company. External reviews are often the stage where patients see the most favorable outcomes, because the reviewer has no financial stake in the decision. Ask your insurer exactly how to request external review and what deadlines apply — appeal windows can be short, and missing a deadline can force you to restart the process.

While You Appeal: Alternative Access

The appeal process can take weeks to months. During this time, you don't have to wait without treatment. Manufacturer savings programs may reduce brand-name costs to $25 to $350 per month for eligible patients. Telehealth platforms offer compounded GLP-1 formulations starting around $149 to $249 per month. Foundayo (orforglipron) is available through LillyDirect starting at $149 per month for the starting dose. And if you're on Medicare, the GLP-1 Bridge program launches July 1, 2026, with a $50 monthly copay for eligible beneficiaries.

Timing Matters

Some plans will continue your medication coverage during the appeal process if you file within a certain window (often 15 days of the denial date). Ask your insurer specifically whether "continuation of benefits" applies during your appeal. This is especially important if you're already taking a GLP-1 and face a denial at re-authorization.

Don't give up after one denial. The insurance appeals process is designed to catch errors in the initial review. Many patients who are genuinely eligible for GLP-1 coverage are approved on appeal — the key is presenting complete, criteria-matched documentation and being persistent through each stage.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. GLP-1 receptor agonists are prescription medications with potential side effects and contraindications. Compounded medications are not FDA-approved. Pricing, coverage, and program details are subject to change—verify directly with providers and insurers.